IdeZ Cysteine Protease Variants for Low-Dose IgG Cleavage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cysteine proteases like IdeS and IdeZ have immunogenicity issues and lower activity against human IgG, particularly IgG1 and IgG2, limiting their therapeutic efficacy and requiring higher doses or immune-suppressive co-administration.
Innovation Solution
Modified IdeZ polypeptides with specific amino acid modifications, such as deletion of the first 20 residues and retention of critical residues at positions 95, 99, and 226, enhance IgG cysteine protease activity and reduce immunogenicity, achieving higher potency comparable to or exceeding IdeS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IdeS or IdeZ is used as a therapeutic agent, then IgG cleavage activity is achieved, but immunogenicity increases leading to anti-drug antibody production
Solution Approach 1:
The invention extracts and modifies specific critical residues (positions 95, 99, and 226) from the IdeZ sequence while removing the N-terminal signal sequence. This selective extraction and modification approach retains the essential IgG-cleaving function while reducing immunogenicity, as the modified polypeptide maintains catalytic activity but exhibits reduced immunogenic properties compared to wild-type IdeZ
Solution Approach 2:
The invention applies parameter changes by modifying amino acid residues at specific positions (95, 99, and 226) in the IdeZ sequence. These parameter modifications alter the protein's immunogenic characteristics while preserving its enzymatic function, resulting in a polypeptide that effectively cleaves IgG with reduced immunogenicity
2Productivity
If IdeZ is used to cleave human IgG, then lower activity is observed particularly against IgG1 and IgG2, but higher doses are required to achieve therapeutic effect
Solution Approach 1:
The invention improves IgG cleavage activity by modifying parameters at critical residues (positions 95, 99, and 226). These parameter changes enhance the catalytic efficiency of the polypeptide against human IgG subclasses, particularly IgG1 and IgG2, thereby reducing the quantity of substance required to achieve the desired therapeutic effect
3Reliability
If higher doses of IdeS or IdeZ are administered to overcome lower activity, then therapeutic effect may improve, but adverse reactions and immune response increase
Solution Approach 1:
The invention modifies critical residues (positions 95, 99, and 226) to enhance IgG cleavage activity, allowing effective therapeutic outcomes at lower doses. This parameter optimization ensures that the modified polypeptide achieves reliable therapeutic effects without requiring higher doses that would trigger increased adverse reactions and immune responses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified IdeZ polypeptides effectively cleave human IgG, especially IgG1 and IgG2, with reduced immunogenicity, allowing for lower doses and fewer adverse reactions, thus improving therapeutic outcomes.
Implementation Method 1
a novel polypeptide which displays IgG cysteine protease activity
Data Source
AI summary
The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab′)2 fragments.